J&J/Medtronic stent litigation
This article was originally published in The Gray Sheet
Executive Summary
Medtronic will seek Supreme Court review after petition from both parties for rehearing - and rehearing en banc - of Palmaz stent patent suit is denied by U.S. Court of Appeals for the Federal Circuit Sept. 29. The court sided with J&J in August, and remanded the case back to its original Delaware district court (1"The Gray Sheet" Aug. 18, 2003, p. 4)...
You may also be interested in...
Litigation In Brief
J&J/Medtronic stent litigation: Supreme Court declines to review ruling awarding Johnson & Johnson/Cordis $271 mil. for infringement of stent patents, including those related to its Palmaz-Schatz('762), denying a writ of certiorari in the case. The U.S. Court of Appeals for the Federal Circuit had denied a rehearing in September 2003 after siding with J&J last August and remanded the case back to its original Wilmington, Del. district court (1"The Gray Sheet" Oct. 6, 2003, In Brief). Medtronic notes that the stents at issue are obsolete...
J&J V. Medtronic: Palmaz-Schatz Infringement Claims Sway Appeals Panel
Medtronic's invocation of the doctrine of equivalents as a legal defense against Johnson & Johnson/Cordis failed to convince a three-judge appeals court panel that Medtronic had not infringed key Cordis patents
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”